Last reviewed · How we verify
AKR1C3-activated Prodrug AST-3424
Activates AKR1C3
Activates AKR1C3 Used for Solid tumors.
At a glance
| Generic name | AKR1C3-activated Prodrug AST-3424 |
|---|---|
| Also known as | AKR1C3-activated Prodrug OBI-3424, AKR1C3-activated Prodrug TH-3424, Aldo-keto Reductase 1c3-activated Prodrug OBI-3424, AST-3424, OBI 3424 |
| Sponsor | SWOG Cancer Research Network |
| Drug class | Prodrug |
| Target | AKR1C3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AST-3424 is a prodrug that is converted into an active form that activates the AKR1C3 enzyme.
Approved indications
- Solid tumors
Common side effects
Key clinical trials
- Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AKR1C3-activated Prodrug AST-3424 CI brief — competitive landscape report
- AKR1C3-activated Prodrug AST-3424 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI